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Abstract
Background: Few data are available on the usefulness of short term treatment with low-medium dose of inhaled
corticosteroids (ICS) in pre-school children with wheezing exacerbations.
Methods: To compare the efficacy of one week treatment with 400 μg b.i.d. nebulized beclomethasone
dipropionate (BDP), plus nebulized 2500 μg prn salbutamol (BDP group), versus nebulized b.i.d. placebo, plus
nebulized prn 2500 μg salbutamol (placebo group), a post-hoc analysis was performed on data obtained in 166
pre-school children with multiple-trigger wheezing, recruited during an acute wheezing episode.
Results: The percentage of symptom-free days (SFDs) was significantly higher in the BDP group (54.7%) than in
the placebo group (40.5%; p = 0.012), with a 35% relative difference. Day-by-day analysis showed that the
percentage of SFDs was already higher in the BDP group after 2 days (7.4%), the difference reaching statistical
significance at day 6 (12.3%; p = 0.035). Cough score was also reduced in the BDP group (0.11) as compared with
the placebo group (0.39; p = 0.048), the difference reaching statistical significance after 5 days of treatment (0.18
and 0.47 respectively; p = 0.047). The mean number of nebulizations per day of prn salbutamol was lower in the
BDP group as compared to the placebo group (0.26 and 0.34, respectively), but the difference was not significant
(p = 0.366). There were no differences in positive effects of BDP treatment between children with and without risk
factors for asthma.
Conclusions: A 1-week treatment with nebulized BDP and prn salbutamol is effective in increasing SFDs and
improving cough in children with wheezing, providing a clinical rationale for the short term use of ICS in episodic
wheeze exacerbations in pre-school children.
Trial Registration: ClinicalTrials.gov (NCT00497523)
Background
Wheezing is a common symptom in pre-school aged
children. Epidemiological studies have demonstrated
that approximately 30% of children have at least 1 epi-
sode of wheezing before the age of 3, with a cumulative
prevalence of wheezing of 50% at the age of 6 [1,2].
Most of these wheezing episodes are induced by viral
upper respiratory tract infections (RTI), which recur fre-
quently in this age group, and the great majority of
young children will have only transient symptoms with
no subsequent increased risk of asthma or allergy later
in life [1-3].
Recurrent pre-school wheezing is a very common clin-
ical problem, with important implications since it may
be associated in developed countries with a remarkable
impact on the healthcare budget [4]. Rates for wheez-
ing-related emergency room visits and hospitalizations
are highest among pre-school children, reflecting not
only the specific morbidity in this population, but also
the lack of conclusive evidence on the efficacy of avail-
able treatments/strategies for these acute events [4-6].
To date, the best treatment for children with intermit-
tent wheezing remains controversial.
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Recently, a variety of evidence-based international
guidelines on the management of wheezing disorders in
pre-school children have been published [3,6-10]. For
persistent wheezing in children under the age of 5, low
dose inhaled corticosteroids (ICS) is recommended as
the preferred controller therapy, with leukotriene modi-
fiers as an alternative. Systematic reviews of controlled
trials evaluating the efficacy of ICS in infants/pre-
schoolers with wheeze or asthma showed that, in those
with frequent symptoms and/or with risk factors for
asthma, ICS therapy improves a variety of relevant out-
comes, including lung function and symptom-free days
(SFDs), wheeze/asthma exacerbation and need for sys-
temic glucocorticosteroids. In these studies, the benefi-
cial effect was independent of age, atopic condition, type
of ICS, mode of delivery and treatment duration
[3,11,12]. This is in agreement with the results of a ran-
domized controlled trial we recently published, in which
276 pre-school children (1-4 years of age) with a history
of recurrent wheezing, recruited during an acute wheez-
ing episode not requiring hospitalization or systemic
ICS, were randomly assigned to 3-month nebulized
treatments with: a) beclomethasone dipropionate (BDP)
b.i.d, plus prn (pro re nata) salbutamol; b) BDP/salbuta-
mol combination prn or c) prn salbutamol [13]. This
trial showed a higher percentage of SFDs in the sub-
group on regular nebulized BDP, as compared with prn
salbutamol. However there were no differences between
regular BDP and the prn combination subgroups on the
primary outcome measure (percentage of SFDs) as well
as on several secondary outcomes, such as symptom
scores, use of relief medication and exacerbation fre-
quency [13].
Systematic reviews and two recent reports have con-
cluded that episodic high-dose inhaled glucocorticoster-
oids may provide some benefit in episodic (viral) wheeze
[11,14-16] but, because of possible side effects (reduced
height) [16], the use of high-dose intermittent steroids
in this age group requires careful consideration [3,16].
Surprisingly, in contrast with the efficacy shown in med-
ium- long-term treatments, the efficacy of short-term
treatment with low-medium dose ICS is poorly documen-
ted in pre-school children with wheezing symptoms.
Here we report the results of a post-hoc analysis, per-
formed in our aforementioned study [13], to evaluate
whether low dose nebulized BDP (400 μg b.i.d), plus prn
salbutamol, was superior to nebulized prn salbutamol in
improving symptoms in the first week of treatment in
pre-school children with a history of recurrent wheez-
ing, recruited during an acute wheezing episode.
Methods
A detailed description of the study design, including
screening and recruitment procedures and statistical
analysis, has been reported in detail elsewhere [13] and
will only be briefly summarized.
Pre-school children (ages 1-4), with a documented his-
tory of at least 3 episodes of wheeze or asthma in the 6
months preceding the visit, evaluated as outpatients for
exacerbation of respiratory symptoms were screened
and characterized [13]. In addition to the three episodes
in the previous 6 months, the included children had a
history of frequent wheeze, induced by other triggers
than viral respiratory tract infection [3]. Nineteen pedia-
tric specialist care units were involved in this rando-
mized, multicenter, double blind, parallel-group,
placebo-controlled trial. Exclusion criteria were: a) his-
tory of severe exacerbations requiring systemic gluco-
corticoids; b) chest infection or hospitalization due to
asthma in the previous 4 weeks; c) treatment with
inhaled glucocorticoids or methyl-xanthine during the
previous 4 weeks; d) treatment with oral glucocorticoids
in the previous 8 weeks. Eligible children entered a 2-
week prospective open run-in period during which they
received only 2500 μg prn nebulized salbutamol for
symptom relief. Patients entered the double-blind treat-
ment phase if they had wheeze and/or cough, and/or
shortness of breath, and/or required relief medication
on at least 7 days of the 2-week run-in period. The
study was performed in accordance with the Declaration
of Helsinki and Good Clinical Practice guidelines. Inde-
pendent ethics committees approved the study protocol,
patient information sheet, and consent forms. A parent
or guardian of each patient provided written informed
consent. Parents/guardians were trained: a) to correctly
use the nebulizer; b) to keep daily records of their
child’s symptoms, recording scores for wheeze, cough,
and shortness of breath on diary cards, using a four-
point rating scale ranging from 0 (no symptoms) to 3
(disabling symptom) [17]; c) to record the number of
occasions during the night they were woken up because
of the child’s asthma symptoms which required rescue
medication for symptom relief.
Children were stratified in two groups on the basis of
the presence or absence of risk factors for developing
persistent asthma [18]: (1) atopic dermatitis or eczema;
(2) asthma in a first-degree relative; (3) blood eosinophi-
lia > 4% demonstrated in the previous 6 months. A 2:1
treatment-to-placebo randomization ratio was used to
expose fewer patients to placebo.
In the original study [13], 3 treatments were tested in
this population over 12 weeks:
a) BDP (Clenil per Aerosol, Chiesi Farmaceutici,
Parma, Italy) 400 μg/vial, one vial b.i.d., plus salbutamol
(Ventmax, Chiesi Farmaceutici, Parma, Italy) 2500 μg/
vial, one vial prn, or b) placebo one vial b.i.d., plus fixed
combination of BDP and salbutamol (Clenil Composi-
tum, Chiesi Farmaceutici, Parma, Italy), 800 μg BDP +
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1600 μg salbutamol/vial, one vial prn, or c) placebo one
vial b.i.d. plus salbutamol 2500 μg/vial, one vial prn. All
drugs were delivered with the same nebulizer (Clenny
aerosol; Medel, Parma, Italy) using a tight-fitting face
mask.
In the current post-hoc analysis we compare the effi-
cacy of regular BDP plus prn salbutamol (BDP group)
vs. regular placebo plus prn salbutamol (placebo group)
on clinical outcomes captured in patients’ diaries during
the first week of treatment.
Groups were compared in terms of percentage of
SFDs at the end of 1-week treatment using an
ANCOVA model with percentage of SFDs as dependent
variable and treatment, country and subgroup as fixed
effects and baseline (run-in) as covariate. A day-by-day
analysis of the percentage of SFDs was also performed
using the same ANCOVA model.
Moreover, a comparison between groups within each
subgroup of the percentage of SFDs at the end of 1-
week treatment was performed using the same
ANCOVA model with also the subgroup*treatment
interaction as fixed effect.
The proportion of patients without asthma symptoms
during the first week of treatment was compared
between groups by means of a logistic regression model
with presence of symptoms during the first week as
dependent variable, treatment, country, subgroup and
percentage of SFDs during run-in as independent
variables.
Each of the three symptom scores was also analyzed
by means of a mixed model for repeated measures with
score at each day as dependent variable, treatment,
country, subgroup, day, treatment*day interaction and
mean value of symptoms during run-in as independent
variables. All tests were considered as explorative.
Results
One hundred sixty-six pre-school children, 98 males and
68 females, (between ages of 1-4) were included in the
post-hoc analysis: 110 were (64 (58.2%) males) in the
BDP group and 56 (34 (60.7%) males) in the placebo
group. The BDP group and the placebo group had simi-
lar baseline characteristics (table 1).
The adjusted mean percentage of SFDs (the study pri-
mary outcome [13]) at the end of the 7-day-treatment
was significantly higher in the BDP group (54.7%) than
in the placebo group (40.5%) (p = 0.012). The propor-
tion of patients without asthma symptoms during the
first week of treatment was significantly higher in the
BDP group than in the placebo group (odds ratio 2.65;
95% CI: 1.08, 6.51, p = 0.033). Day-by-day analysis
showed that the adjusted mean percentage of SFDs was
already higher after 2 days of treatment in the BDP
group (55.0%) as compared with the placebo group
(47.5%) with a 7.4% difference, the difference between
groups reaching statistical significance after 6 days of
treatment (52.4% in BDP group, 40.1% in placebo group
with a 12.3% difference, 95% CI of difference: 0.88, 23.8;
p = 0.035; Figure 1). At the end of the 7-day-treatment,
the adjusted mean coughing score was also lower in the
BDP group (0.11) compared to the placebo group (0.39)
with a difference of -0.29 (95% CI of difference: -0.568,
-0.002; p = 0.048); the between-group difference reached
statistical significance as early as day 5 of treatment (dif-
ference between BDP and placebo group is -0.29; p =
0.047; Figure 2). No significant differences were found
between the two groups with respect to other secondary
outcomes such as nocturnal awakenings, wheezing
score, shortness of breath score and symptom score (p >
0.05, all comparisons, data not shown) although all were
numerically in favour of BDP. The positive effects of
BDP treatment on percentage of SFDs were similar in
children with and without risk factors for asthma, the
difference in adjusted mean percentage of SFDs in the
first week of treatment being 2.06% (p = 0.75). Notably,
the difference between BDP and placebo was significant
in the subgroup of children with risk factors for asthma,
with 19.06% more SFDs as compared to placebo (p =
Table 1 Baseline characteristics
Beclomethasone (BDP group) (N = 110) Salbutamol (Placebo group) (N = 56)
Male, n (%) 64 (58.2) 34 (60.7)
Risk factors for asthma, n (%) 57 (51.8) 30 (53.6)
Age, yr 2.35 ± 0.81 2.29 ± 0.78
Weight, kg 15.4 ± 2.82 14.9 ± 2.74
Height, cm 97.5 ± 9.19 96.0 ± 9.61
Duration of wheezing, yr 1.59 ± 0.87 1.43 ± 0.82
Symptom-free days, % 21.4 ± 18.3 25.9 ± 21.0
Daily coughing score 1.43 ± 0.71 1.35 ± 0.80
Daily Salbutamol use, na 0.49 ± 0.48 0.42 ± 0.35
Values of symptom-free days, daily coughing score and daily salbutamol use are mean of the 2-week run-in period ± SD. Beclomethasone = beclomethasone
dipropionate; a number of nebulizations per day.
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0.014) but it was not significant in the subgroup without
risk factors (p = 0.257) despite 9.24% more SFDs.
The adjusted mean number of nebulisations per day of
prn salbutamol was lower in the BDP group as com-
pared to the placebo group (0.26 and 0.34, respectively)
although the difference was not significant (p = 0.366).
Discussion
The results of this post-hoc analysis show the efficacy of
a short treatment with nebulized BDP in pre-school
children with a mild-to-moderate wheezing episode not
requiring hospitalization or systemic corticosteroids.
Previous studies on intermittent treatment with
inhaled glucocorticoids in pre-school wheeze exacerba-
tions led to conflicting results [3,11,12]. Three studies
suggested that initiating ICS therapy at the early signs of
episodic wheezing/asthma exacerbation in pre-school
children does not result in reduction in oral
corticosteroid use [19-21]. These studies, however, were
small and used different time points for intervening
with medication, thus limiting interpretation of results.
Also a study performed in 411 infants, enrolled at one
month of age to evaluate the effects of ICS initiated
after a three-day episode of wheezing, did not demon-
strate any short-term benefit during the acute manifes-
tation or on the progression from episodic to persistent
wheezing [22]. Lack of effect might be related to the
specific pathophysiology of wheezing episodes present in
young children.
More recently, Bacharier and co-workers, in a rando-
mized, double-blind, placebo-controlled trial compared
the efficacy of 7 day treatment with either budesonide
inhalation suspension (1 mg twice daily), montelukast (4
mg daily), or placebo in addition to salbutamol at the
early signs of RTI in pre-school children with moderate-
to severe intermittent wheezing [15]. No differences in
the proportion of episode-free days, oral corticosteroid
and health care use, quality of life, or linear growth was
observed in the three treatment groups during the 12-
month trial. However, during RTI, administration of
budesonide and of montelukast led to significant reduc-
tion of episode severity as compared with conventional
therapy with reductions in trouble breathing and inter-
ference with activity scores. The efficacy was most evi-
dent during the peak symptom period of the first 48
hours of illness and in children with positive asthma
predictive indices [15,18].
Our results extend these observations showing the
efficacy of low dose nebulized BDP, detectable a few
days after the beginning of treatment. In contrast with
Bacharier’s study [15], we did not see any significant dif-
ference in the response to treatment between children
with positive or negative asthma predictive indices either
in the original 12-week trial or in this 1-week analysis.
This is in agreement with previous reports where no dif-
ferences in response to ICS were reported by pre-school
children with and without risk factors for asthma,
including atopic condition, sensitization to inhaled aller-
gens, and eczema [12,23,24]. Differences in the study
design and in the patient population may explain the
discrepancy between Bacharier’s study [15] and ours.
Nevertheless, we found that the increase in the percen-
tage of SFDs after 1 week of BDP treatment, as com-
pared to placebo, was significant only for the subgroup
of children with risk factors.
Finally, an interesting hypothesis is that the episodic
use of an ICS (e.g. BDP) during acute RTI could
decrease an important source of future respiratory mor-
bidity, in these children, i.e. airway inflammation and
remodeling, leading to a medium-long-term down regu-
lation of the severity of the subsequent exacerbations
[13].
Figure 1 Percentage of symptom-free days in the first week of
treatment; each day represents the cumulative percentage of
symptom-free days in the preceding period; on day 1 the data
is relative to the % of symptom-free patients; * p < 0.05
between groups.
Figure 2 Mean coughing score in the first week of treatment;
each day represents the cumulative mean coughing score; * p
< 0,05 between groups.
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The percentage of SFDs is a frequently used measure
for asthma control and reflects the multiple components
of asthma disease burden. Although often informative in
comparing the effects of long-term controller medica-
tions for asthma in patients with chronic symptoms, it
has been shown to be also sufficiently sensitive to detect
treatment effects among children with an episodic disor-
der, such as severe intermittent asthma [15]. The
demonstration of the efficacy of a short treatment with
BDP in the present trial is of interest even from a safety
point of view, considering that we detected no systemic
effects of the 12 weeks treatment in the original trial by
measuring cortisol at the beginning and end of treat-
ment [13]. The systemic side effects of corticosteroids
are considered negligible in short term therapies but
this is in contrast with recent findings. A study evaluat-
ing the immune response of children aged three to 17,
arriving at the emergency room with an asthma attack
showed an immune suppression in children receiving
oral corticosteroids [25]. In light of this new evidence,
the use of nebulized rather than oral corticosteroids
may be preferable even for short term treatments.
The limit of the present study is that the post-hoc
analyses were based only on the data of the first week of
a 3-month clinical trial and P-values of these analyses
were unadjusted for multiplicity.
Conclusions
In conclusion, this study shows the short term efficacy
of a one week nebulized BDP plus salbutamol as needed
treatment on SFDs and coughing in young children with
wheezing. Our findings, along with recent pharmacolo-
gical reports showing the rapid onset of action of ICS
[26,27] could provide a clinical rationale for the short
term use of ICS in episodic wheeze, one of the most fre-
quent recurrent respiratory disorders in pre-school
children.
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